A practical reference on 冻干粉: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Clusters can be found in all classes of chemical compounds. According to the commonly accepted definition, a cluster consists minimally of a triangular set of atoms that are directly bonded to each other. But metal–metal bonded dimetallic complexes are highly relevant to the area. Clusters occur in "pure" inorganic systems, organometallic chemistry, main group chemistry, and bioinorganic chemistry. The distinction between very large clusters and bulk solids is increasingly blurred. This interface is the chemical basis of nanoscience or nanotechnology and specifically arise from the study of quantum size effects in cadmium selenide clusters. Thus, large clusters can be described as an array of bound atoms intermediate in character between a molecule and a solid.
A man is arrested on suspicion of attempted murder after four people were injured when they were hit by a car being driven on the wrong side of the road in Shaftesbury Avenue, central London. King Charles III delivers the Royal Christmas Message from London's Fitzrovia Chapel, where he praises health workers and calls for unity following the summer riots. Archbishop of York Stephen Cottrell delivers a Christmas message in place of the Archbishop of Canterbury, doing so as he prepares to assume acting charge of the Church of England. 26 December – Data collected by MRI Software indicates a 4% decrease in the number of Boxing Day shoppers compared to the same day in 2023. 27 December The Prime Minister pays tribute to Nick Starmer, his younger brother who died from cancer the previous day. Conservative leader Kemi Badenoch expresses her condolences. Flights to and from some of the UK's major airports, including Gatwick and Manchester, are disrupted due to fog. Former Conservative Justice Secretary David Gauke, who is leading a review into sentencing and prison overcrowding, calls for greater use of open prisons in order to ease the pressure on closed category prisons. A man is charged with four counts of attempted murder and remanded in custody over an incident involving a car in London on Christmas Day. 28 December – Fog continues to disrupt flights at UK airports. 29 December Weather warnings for rain, snow, and winds of up to 70 mph are issued for parts of the UK on New Year's Eve and New Year's Day.
Very Common (> 10% incidence) adverse effects Confusion Constipation (usually transient, but can persist in some) Decreased memory Diarrhea (usually transient, but can persist in some) Dry mouth ECG changes – usually benign changes in T waves Hand tremor (usually transient, but can persist in some) with an incidence of 27%. If severe, the psychiatrist may lower lithium dosage, change lithium salt type or modify lithium preparation from long to short-acting (despite lacking evidence for these procedures) or use pharmacological help Headache Hyperreflexia – overresponsive reflexes Leukocytosis – elevated white blood cell count Muscle weakness (usually transient, but can persist in some) Myoclonus – muscle twitching Nausea (usually transient) Polydipsia – increased thirst Polyuria – increased urination Renal (kidney) toxicity which may lead to chronic kidney failure, although some cases may be misattributed Vomiting (usually transient, but can persist in some) Vertigo Common (1–10%) adverse effects Acne Extrapyramidal side effects – movement-related problems such as muscle rigidity, parkinsonism, dystonia, etc. Euthyroid goitre – i.e. the formation of a goitre despite normal thyroid functioning Hypothyroidism – a deficiency of thyroid hormone. Common among bipolar patients; lithium increases rates. Hair loss/hair thinning Weight gain – 5% incidence, tends to start fast and then plateau. Usually ends at 1–2 kg. A 2022 systematic review and meta-analysis show an insignificant amount of weight gain of 0.462 kg, with higher weight gain associated with shorter use periods.
In August 2004, Palatin signed an agreement with King Pharmaceuticals to co-develop bremelanotide in the US and jointly license it outside the US; King paid Palatin $20 million upfront. Palatin conducted Phase II trials of intranasal bremelanotide in both female sexual dysfunction (FSD) and male erectile dysfunction (ED), but these trials were halted by the FDA in 2007, due to increased blood pressure in clinical trial subjects; Palatin stopped development of the intranasal formulation in 2008. Four trials were conducted in ED, the last being a Phase IIb published in 2008. King terminated the co-development agreement shortly after the FDA halted the trials. The drug was then reformulated to be delivered by injection and trials continued in FSD. A phase II dose-finding trial in FSD in which the drug was administered 45 minutes before sex showed promise at the highest dose and only transient signs of high blood pressure; two Phase III trials were launched at the end of 2014. Palatin launched the Phase III trials with bremelanotide administered via an autoinjector. In 2014, Palatin licensed European rights to bremelanotide to Gedeon Richter Plc. for around $10 million, and Palatin received a milestone payment of around $3 million when it started the Phase III trials in the US. In September 2016, Palatin and Gedeon Richter terminated that agreement. In November 2016, Palatin announced results of the Phase III trials, and shortly thereafter began seeking a partner to complete development in the US.
== Collections == The London Archives holds the records of the ILEA from its conception until its closure in 1990; further material for the archive was received in 2004 and 2005. The Institute of Education, University College London holds extensive material relating to groups and individuals involved in work for the ILEA. These include:
Sources: en.wikipedia.org
"Instant tea", similar to freeze-dried instant coffee and an alternative to brewed tea, can be consumed either hot or cold. Instant tea was developed in the 1930s, with Nestlé introducing the first commercial product in 1946, while Redi-Tea debuted instant iced tea in 1953. Additives, such as chai, vanilla, honey, fruit or powdered milk, are commonly used. During the Second World War, British and Canadian soldiers were issued instant tea in their composite ration ("compo") packs. These blocks of instant tea, powdered milk, and sugar were not always well received. As Royal Canadian Artillery Gunner, George C Blackburn observed:
== Dietary recommendations == The US National Academy of Medicine updated Dietary Reference Intakes (DRIs) in 2001 for vitamin A, which included Recommended Dietary Allowances (RDAs). The tolerable upper intake level (UL) is 3000 μg/day. For children ages 1-3 years the vitamin A RDA and UL are 300 and 600 μg/day, respectively, for children ages 4-8 years 400 and 900 μg/day. People consuming cod liver oil as a source of omega-3 fatty acids should pay attention to how much vitamin A and vitamin D this adds to their diet. For infants up to 12 months, there was not sufficient information to establish an RDA, so Adequate Intake (AI) is shown instead. As for safety, tolerable upper intake levels (ULs) were also established. For ULs, carotenoids are not added when calculating total vitamin A intake for safety assessments.
The T-cell receptor (TCR) is a protein complex, located on the surface of T cells (also called T lymphocytes). They are responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is biologically degenerate (that is, many TCRs recognize the same antigen peptide, and many antigen peptides are recognized by the same TCR). The TCR is composed of two different protein chains (that is, it is a heterodimer). In humans, in 95% of T cells the TCR consists of an alpha (α) chain and a beta (β) chain (encoded by TRA and TRB, respectively), whereas in 5% of T cells the TCR consists of gamma and delta (γ/δ) chains (encoded by TRG and TRD, respectively). This ratio changes during ontogeny and in diseased states (such as leukemia). It also differs between species. Orthologues of the 4 loci have been mapped in various species. Each locus can produce a variety of polypeptides with both constant and variable regions. When the TCR engages with antigenic peptide and MHC (peptide/MHC), the T lymphocyte is activated through signal transduction (that is, a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors). Based on the initial receptor-triggering mechanism, the TCR is classified as belonging to the family of non-catalytic tyrosine-phosphorylated receptors (NTRs).
== Taxonomy == FishBase recognizes four species in the genus. In addition to these, evidence suggests that a fifth species, A. arapaima, should be recognized (this being the widespread, well-known species, otherwise included in A. gigas).
Codtrace. Archived 1 February 2016 at the Wayback Machine. fishbase.org – Scientific Names for Gadus Fisheries Heritage website, Newfoundland and Labrador (archived) Long term trends in Norwegian cod fisheries – the pioneers Species factsheet on cod from the UK Sea Fish Industry Authority (PDF, 2MB) "Cod" . New International Encyclopedia. 1905.
Sources: en.wikipedia.org
== Function == 5-HEDH functions as a highly specific oxidizer of 5(S)-HETE to 5-oxo-ETE; no functional importance has yet been ascribed to its ability in similarly oxidizing other 5(S)-hydroxyl fatty acids. 5-Oxo-ETE stimulates a wide range of biological activities far more potently and powerfully than 5(S)-HETE. For example, it is 30–100-fold more potent in stimulating cells that promote inflammation and allergy reactions such as neutrophils, monocytes, macrophages, eosinophils, and basophils and is more potent than 5-HETE in stimulating various types of cancer cells to grow. Furthermore, 5-oxo-ETE appears to be involved in various animal and human reactions: injected into the skin of rabbits, it causes a severe edema with an inflammatory cell infiltrate resembling an urticaria-like lesion; it is present in bronchoalveolar lavage fluid from cats undergoing experimentally induced asthma; it stimulates the local accumulation of eosinophils, neutrophils, and monocytes when injected into the skin of humans; and it has been extracted from scales of psoriatic patients. Most if not all of these allergic and inflammatory conditions as well as rapidly growing cancerous lesions are associated with oxidative stress. Studies therefore suggest that 5-HEDH contributes to the development and progression of these reactions and diseases by being responsible for generating 5-oxo-ETE.
Enriched uranium was first manufactured in the early 1940s when the United States and the United Kingdom began their nuclear weapons programs. Later in the decade, France and the Soviet Union began their nuclear weapons and nuclear power programs. Depleted uranium was originally stored as an unusable waste product (uranium hexafluoride) in the hope that improved enrichment processes could extract additional quantities of the fissionable 235U isotope. This re-enrichment recovery of the residual uranium-235 is now in practice in some parts of the world; e.g. in 1996 over 6,000 tonnes (6,600 short tons) were upgraded in a Russian plant. In the 1970s, the Pentagon reported that the Soviet military had developed armor plating for Warsaw Pact tanks that NATO ammunition could not penetrate. The Pentagon began searching for materials to make denser armor-piercing projectiles. After testing various metals, ordnance researchers settled on depleted uranium. The US and NATO militaries used DU penetrator rounds in the 1991 Gulf War, the Bosnia war, bombing of Serbia, the 2003 invasion of Iraq, and 2015 airstrikes on ISIS in Syria. It is estimated that between 315 and 350 short tons (286 and 318 t) of DU were used in the 1991 Gulf War.
The Li-ion battery recycling rate is often misconstrued to be 5%, in reality, insufficient research exists to determine the exact figure. The European Union estimates 49% of portable batteries sold were collected for recycling in 2023, whilst the UK estimates 45% as of 2026. New EU legislation requires 70% of collected Li-ion battery material to be recovered through recycling by 2031, which must include recovery rates of 80% for lithium and 95% for cobalt, nickel, and manganese; however, no recycled lithium has re-entered the EU as of 2023. These measures aim to aid sustainability efforts and reduce pressure on raw material extraction, as demand for lithium and cobalt is expected to increase 8-fold by 2040, far exceeding current production capabilities. Most research focuses on the recovery of active materials, especially lithium which is a critical raw material; however, through advanced recycling techniques and more sustainable design considerations, electrolytes, binders, and separators can also be recycled. Recycling is a multi-step process, starting with the storage of batteries before disposal, followed by manual testing, disassembling, and finally the chemical separation of battery components. Re-use of the battery is preferred over complete recycling as there is less embodied energy in the process. As these batteries are a lot more reactive than classical vehicle waste like tire rubber, there are significant risks to stockpiling used batteries.
==== First CONMEBOL and regional tournaments (1945–1946) ==== Colombia made their Copa América debut at the 1945 tournament in Chile, their first appearance in an official CONMEBOL competition. With no professional league or national selection system in place, the squad was built almost entirely around Junior de Barranquilla, then one of the strongest amateur sides on the Caribbean coast, and every player was registered simply as an amateur. Roberto Meléndez acted as player-manager, appearing on the wing while also selecting the side. Drawn against Brazil, Uruguay, Argentina, Chile, Ecuador and Bolivia, Colombia lost their first four matches but finished with a 3–1 win over Ecuador and a 3–3 draw with Bolivia to place fifth of seven.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.